INDEMNITY AGREEMENTIndemnity Agreement • April 2nd, 2014 • Lumena Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , is made by and between LUMENA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
LUMENA PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • April 2nd, 2014 • Lumena Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of March 7, 2014, by and among LUMENA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and the entities listed on EXHIBIT A hereto (each, an “Investor” and together the “Investors”).
LICENSE AGREEMENTLicense Agreement • February 28th, 2014 • Lumena Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
For the management of the business and for the conduct of the affairs of the Company, and in further definition, limitation and regulation of the powers of the Company, of its directors and of its stockholders or any class thereof as the case may be, it is further provided that:
LICENSE AGREEMENT BETWEEN LUMENA PHARMACEUTICALS, INC. AND SATIOGEN PHARMACEUTICALS, INC. EFFECTIVE AS OF FEBRUARY 8, 2011License Agreement • April 2nd, 2014 • Lumena Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS LICENSE AGREEMENT (this “Agreement”) is entered into as of February 8, 2011 (the “Effective Date”), by and between Lumena Pharmaceuticals, Inc. (“Licensee”), a corporation organized and existing under the laws of the State of Delaware, and Satiogen Pharmaceuticals, Inc. (“Satiogen”), a corporation organized and existing under the laws of the State of Delaware. Licensee and Satiogen are sometimes referred to herein individually as a “Party” and collectively as “Parties.” The Parties agree as follows:
LICENSE AGREEMENT BETWEEN LUMENA PHARMACEUTICALS, INC. AND PFIZER INC. DATED June 1, 2012License Agreement • April 2nd, 2014 • Lumena Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS LICENSE AGREEMENT (this “Agreement”) is entered into as of June 1, 2012 (the “Effective Date”), by and between Lumena Pharmaceuticals, Inc. (“Lumena”), a corporation organized and existing under the laws of the State of Delaware, and Pfizer Inc. (“Pfizer”), a corporation organized and existing under the laws of the State of Delaware. Lumena and Pfizer are sometimes referred to herein individually as a “Party” and collectively as “Parties.” The Parties agree as follows:
Research Triangle Park, NC 27709Lumena Pharmaceuticals, Inc. • April 2nd, 2014 • Pharmaceutical preparations
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR EXTRAMURAL-PHS CLINICAL RESEARCHResearch and Development Agreement • April 2nd, 2014 • Lumena Pharmaceuticals, Inc. • Pharmaceutical preparations • District of Columbia
This Agreement (“CRADA”) is based on the model Cooperative Research and Development Agreement (“Model CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
CONSULTING AGREEMENTConsulting Agreement • April 2nd, 2014 • Lumena Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS CONSULTING AGREEMENT (“Agreement”) is entered into as of July 2, 2012 by and between LUMENA PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business located at 2520 Meridian Parkway, Suite 400, Durham, NC 27713 (“Company”), and ALANA MCNULTY (“Consultant”).
LUMENA PHARMACEUTICALS, INC. INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • February 28th, 2014 • Lumena Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of the 19th day of June, 2012, by and among LUMENA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and the entities listed on EXHIBIT A hereto (each, an “Investor” and together the “Investors”).
December 17, 2012 Michael GreyLumena Pharmaceuticals, Inc. • April 2nd, 2014 • Pharmaceutical preparations • California
December 20, 2012 Alejandro Dorenbaum, M.D.Lumena Pharmaceuticals, Inc. • April 2nd, 2014 • Pharmaceutical preparations • California
Lumena Pharmaceuticals, Inc. (the “Company”) is pleased to offer you the position of Chief Medical Officer on the terms set forth in this letter agreement (the “Agreement”). Your start date with the Company will be January 21, 2013, or such other date as we may mutually agree, subject to your signing and returning both this letter and the Company’s standard Employee Proprietary Information and Inventions Agreement.
February 4, 2014 Susan DubéLumena Pharmaceuticals, Inc. • April 2nd, 2014 • Pharmaceutical preparations
HIGH BLUFF RIDGE AT DEL MAR OFFICE LEASEOffice Lease • February 28th, 2014 • Lumena Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This SUMMARY OF BASIC LEASE INFORMATION AND DEFINITIONS (“Summary”) is hereby incorporated into and made a part of the attached Office Lease which pertains to the Building described in Section 1.4 below. All references in the Lease to the “Lease” shall include this Summary. All references in the Lease to any term defined in this Summary shall have the meaning set forth in this Summary for such term. Any initially capitalized terms used in this Summary and any initially capitalized terms in the Lease which are not otherwise defined in this Summary shall have the meaning given to such terms in the Lease. If there is any inconsistency between the Summary and the Lease, the provisions of the Lease shall control.
